Browse the evidence

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe caloric restriction, dehydration, and acute kidney injury, particularly in unmonitored or high-risk populations.

If you are prescribed a GLP-1 agonist (like Ozempic or Mounjaro), do not use it without medical supervision. Ensure you are screened for eating disorders and receive dietary counseling. Watch for signs of extreme food aversion or dehydration, and stop the medication if you lose weight too rapidly or feel severe nausea/diarrhea, seeking immediate medical attention if you experience kidney issues.

GLP-1 receptor agonists can trigger or exacerbate restrictive eating behaviors and food aversions, mimicking Avoidant/Restrictive Food Intake Disorder (ARFID), in patients with obesity and those with rare genetic disorders of obesity.

Be aware that GLP-1s can make you lose interest in food entirely. If you find yourself unable to eat enough to maintain your health, or if you develop strong aversions to specific foods, inform your doctor immediately. This may require dose reduction or discontinuation.

Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.

If you start Tirzepatide, expect gastrointestinal issues like nausea or diarrhea, especially in the first month. These are common reasons for stopping treatment. Starting at the lowest dose (5mg) might help you tolerate the medication better, as higher doses are linked to later but potentially more severe onset of side effects. Monitor your symptoms closely during the first few weeks.

Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.

If you are over 65 and start Tirzepatide, be extra vigilant in the first two weeks. Side effects like nausea or dizziness may hit you much sooner than they would for a younger person. Report any severe symptoms to your doctor immediately, as discontinuation rates are higher in this age group.

GLP-1 receptor agonist use is associated with an increased risk of hair loss (alopecia, telogen effluvium), with incidence potentially correlated with the magnitude of weight loss.

If you are using a GLP-1 agonist (like Ozempic or Mounjaro) and notice increased shedding or thinning, this is a known potential side effect, often linked to rapid weight loss or hormonal shifts. It does not happen to everyone, and in some cases, hair regrowth has been observed. Do not stop your medication abruptly without consulting your doctor; discuss monitoring strategies or temporary pauses if the hair loss is severe.

Therapeutic inhibition of myostatin using inhibitors or antibodies is a potential treatment for muscle-wasting disorders like Duchenne muscular dystrophy, sarcopenia, and cachexia, but long-term safety and functional integrity are concerns.

Myostatin inhibitors are experimental treatments for serious muscle-wasting diseases. They are not available or recommended for healthy individuals. If you have a wasting disorder, consult a specialist about clinical trials. Do not attempt to self-administer myostatin blockers.

Personalized nutrition does not significantly reduce fasting blood glucose compared to control diets in adults with prediabetes or type 2 diabetes.

While personalized nutrition improves HbA1c and postprandial responses, it may not significantly lower fasting blood glucose compared to standard diets in the short term. Patients should focus on overall glycemic control (HbA1c) rather than just fasting numbers.

Tilorone attenuates high-fat diet-induced hepatic steatosis and improves glucose tolerance in mice by enhancing BMP9-Smad1/5/8 signaling and upregulating PPARγ expression.

This preclinical study suggests that tilorone, administered via intraperitoneal injection, can reduce liver fat and improve glucose metabolism in mice on a high-fat diet by activating specific signaling pathways. However, as this is an animal study using a synthetic small molecule administered via injection, it does not currently provide a direct, actionable protocol for human dietary or lifestyle intervention. Clinical trials are required to determine efficacy and safety in humans.

Liraglutide is associated with higher rates of anxiety and medication switching compared to Tirzepatide and Semaglutide.

If you have a history of anxiety, Liraglutide might not be the best choice, as this study found it was associated with higher anxiety rates and more medication switches compared to Tirzepatide and Semaglutide. Tirzepatide may offer a better balance of efficacy and tolerability for you.

GLP-1 receptor agonists are associated with reduced risks of various psychiatric disorders, including substance use disorders, suicidal ideation, and dementia, suggesting potential neuroprotective benefits beyond weight management.

While GLP-1RAs are primarily used for weight loss, emerging large-scale data suggests they may also reduce the risk of certain psychiatric conditions like dementia and substance use disorders. However, these benefits are observational, and more research is needed to confirm if GLP-1RAs directly cause these improvements or if other factors are involved.

Gut microbiome-derived short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate exert anti-obesity effects by activating G protein-coupled receptors (GPR43/GPR41) and inhibiting histone deacetylase (HDAC), which stimulates the release of satiety hormones (GLP-1, PYY) and increases energy expenditure.

To leverage the benefits of short-chain fatty acids, focus on consuming high-fiber carbohydrates that gut bacteria can ferment. This supports the natural production of SCFAs like butyrate and propionate, which help regulate appetite hormones and metabolism. While the exact dosing is complex, a diet rich in diverse plant fibers is the most accessible way to support this mechanism.

Bile acids, specifically secondary bile acids like ursodeoxycholate (UDCA) and lithocholate (LCA), and the activation of the TGR5 receptor, contribute to metabolic improvements and weight loss by stimulating GLP-1 release and increasing adipose tissue thermogenesis.

Dietary changes that alter bile acid metabolism, such as those seen with specific fiber intakes or weight loss itself, can positively impact metabolic health. While direct bile acid supplementation is complex, maintaining a healthy gut microbiome supports the natural production of beneficial secondary bile acids.

In patients with type 2 diabetes and diabetic kidney disease (specifically macroalbuminuria A3), subcutaneous semaglutide significantly reduces albuminuria and improves glycemic control (HbA1c) over a 6-month period, while showing no statistically significant impact on blood pressure, weight, or estimated glomerular filtration rate (eGFR).

For patients with diabetes and kidney disease, semaglutide is an effective treatment to lower blood sugar and reduce kidney stress (albuminuria), even if it doesn't significantly change weight or blood pressure in the short term. It is safe and should be considered, especially for those with high albumin levels.

Semaglutide use in patients with pre-existing retinopathy is associated with an increased risk of retinal complications, likely due to rapid glycemic improvement, requiring cautious use.

If you have Type 2 Diabetes and existing eye disease (retinopathy), discuss the potential risk of worsening eye complications with your doctor before starting semaglutide. This risk is linked to how quickly blood sugar improves and is rare in those without pre-existing eye issues.

GLP-1 receptor agonists may increase the risk of thyroid cancer (specifically medullary thyroid cancer) and biliary tract disease, requiring monitoring despite potential cancer benefits.

GLP-1 RAs carry a black box warning for thyroid cancer, particularly medullary thyroid cancer. Patients with a personal or family history of MTC or MEN2 syndrome should not use these drugs. For others, the risk appears low in RCTs but higher in observational studies, so regular monitoring is advised.

The association between GLP-1 RAs and reduced cancer risk is not uniform across the class; liraglutide and semaglutide show reduced risk, while dulaglutide shows a neutral association.

While the class as a whole does not increase cancer risk, the protective effect may vary by drug. Liraglutide and semaglutide show signals of reduced risk, whereas dulaglutide shows a neutral effect. This suggests that the choice of GLP-1 RA might matter for long-term oncological safety, though more research is needed.

GLP-1 receptor agonists (GLP-1RAs) used for weight management and obesity are associated with a significantly higher risk of psychiatric adverse events, including suicidal behavior, panic attacks, and depressive disorders, compared to their use in diabetes treatment.

If you are using a GLP-1 medication (like semaglutide or tirzepatide) for weight loss, be aware that reports of mood changes, including anxiety, panic, or suicidal thoughts, are higher in weight management users than in diabetes users. Discuss these risks with your doctor before starting. If you experience sudden mood changes, contact your provider immediately. This does not mean everyone will experience this, but it is a known signal to monitor.

GLP-1 receptor agonists show potential therapeutic benefits for psychiatric conditions, including depression, anxiety, binge-eating disorder, and substance use disorders, though evidence quality varies.

GLP-1 agonists may help with depression, anxiety, and binge-eating disorder, in addition to weight loss. However, results for addiction (like alcohol) are mixed. Consult a psychiatrist or physician to see if these medications might support your mental health treatment, especially if you have obesity or diabetes.

Targeting the glucagon receptor (GCGR) with antagonists can promote beta-cell regeneration and improve beta-cell identity in Type 2 Diabetes models.

Research suggests that blocking the glucagon receptor (GCGR) might help regenerate insulin-producing beta cells in people with Type 2 Diabetes. This is a newer area of treatment development, moving beyond just replacing insulin to trying to repair the pancreas itself. While promising in animal studies, this is not yet a standard clinical practice for all patients.

Tirzepatide therapy significantly improves cardiac function (LVEF) and reduces cardiac stress (NT-proBNP) in patients with heart failure over a six-month period.

If you have heart failure and are prescribed tirzepatide, expect measurable improvements in your heart's pumping ability (LVEF) and reduced stress on your heart (NT-proBNP) within six months. This medication also improves your ability to walk and your overall quality of life. Ensure you are monitored by your healthcare provider for dosage adjustments and side effects.

Tirzepatide therapy significantly improves functional capacity (6MWT distance) and quality of life (KCCQ scores) in patients with heart failure.

If you have heart failure and are prescribed tirzepatide, you may experience an increased ability to walk and an overall improvement in your quality of life within six months. This means you might feel less short of breath and more capable of performing daily activities. Discuss these potential benefits with your healthcare provider.

Carriage of rare, potentially deleterious variants in the GLP1R gene is associated with an increased risk of Type 2 Diabetes (T2D) and higher HbA1c levels, particularly in individuals with obesity.

If you have a family history of T2D and carry rare GLP1R variants (often identified through specialized genetic testing), maintaining a healthy weight is critically important. This paper shows that the genetic risk for diabetes is significantly amplified if you are obese. Weight management is not just general advice but a specific counter-measure for this genetic profile.

Calculating the Area Under the Curve (AUC) ratio of the Insulinogenic Index (IGI) during a 70g carbohydrate meal tolerance test provides a superior evaluation of pancreatic beta-cell function and glucose variability compared to the Delta (increment) ratio method in Type 2 Diabetes Mellitus patients.

For Type 2 Diabetes patients undergoing a meal tolerance test with 70g of carbohydrates, using the Area Under the Curve (AUC) method to calculate the Insulinogenic Index provides a more reliable assessment of pancreatic function than the simpler Delta ratio method. This is because the AUC method shows less data overlap and stronger correlation with daily glucose variability, offering a clearer view of how the pancreas handles carbohydrate loads.

Transoral outlet reduction (TORe) using argon plasma coagulation (APC) induces a significant increase in postprandial peptide YY (PYY) levels, particularly in patients who have undergone cholecystectomy, whereas APC combined with suturing does not produce this effect.

If you have regained weight after gastric bypass due to a stretched connection (anastomosis), endoscopic tightening with argon plasma coagulation (APC) may help restore your body's natural satiety signals, specifically Peptide YY (PYY). This effect is particularly strong if you have had your gallbladder removed. This suggests that choosing the right endoscopic technique (APC vs. suturing) matters for hormonal health and potentially long-term weight management.